AOLS (Aeolus Pharmaceuticals) Scaled Net Operating Assets: -0.11 (As of Jun. 2017)


What is Aeolus Pharmaceuticals Scaled Net Operating Assets?

Aeolus Pharmaceuticals AOLS Scaled Net Operating Assets is -0.11 as of Jun. 2017.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aeolus Pharmaceuticals's operating assets for the quarter that ended in Jun. 2017 was $0.39 Mil. Aeolus Pharmaceuticals's operating liabilities for the quarter that ended in Jun. 2017 was $0.59 Mil. Aeolus Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2017 was $1.77 Mil. Therefore, Aeolus Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2017 was -0.11.

Aeolus Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Scaled Net Operating Assets Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.00 -0.13 0.04 0.02 0.02

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.01 0.06 0.06 -0.11

AOLS vs RDGL, PCYN, YBAO: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aeolus Pharmaceuticals Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Scaled Net Operating Assets falls into.


Aeolus Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aeolus Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Sep. 2016 is calculated as

Scaled Net Operating Assets (SNOA)(A: Sep. 2016 )
=(Operating Assets (A: Sep. 2016 )-Operating Liabilities (A: Sep. 2016 ))/Total Assets (A: Sep. 2015 )
=(1.012-0.972)/1.777
=0.02

where

Operating Assets(A: Sep. 2016 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4.167 - 3.155
=1.012

Operating Liabilities(A: Sep. 2016 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.972 - 0 - 0
=0.972

Aeolus Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2017 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2017 )
=(Operating Assets (Q: Jun. 2017 )-Operating Liabilities (Q: Jun. 2017 ))/Total Assets (Q: Mar. 2017 )
=(0.391-0.587)/1.765
=-0.11

where

Operating Assets(Q: Jun. 2017 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.794 - 0.403
=0.391

Operating Liabilities(Q: Jun. 2017 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.587 - 0 - 0
=0.587

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.11 mean?
Aeolus Pharmaceuticals (AOLS) has a Scaled Net Operating Assets of -0.11 as of Jun. 2017. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Scaled Net Operating Assets too high?
Aeolus Pharmaceuticals' current Scaled Net Operating Assets is -0.11.
How does Aeolus Pharmaceuticals' Scaled Net Operating Assets compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Scaled Net Operating Assets of -0.11 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Scaled Net Operating Assets is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Scaled Net Operating Assets of -0.11. The current Scaled Net Operating Assets is -0.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Scaled Net Operating Assets is -0.11 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.